Sunitinib Malate Market Size, Share, Analysis Report | Marketresearch
1 of 5
about:reader?url=https%3A%2F%2Fwww.marketresearchengine.com...
marketresearchengine.com
Sunitinib Malate Market By Product (Purity: >99%, Purity: >98%, Purity: >97%); By Application (Pancreatic Neuroendocrine Tumours, Kidney Cancer, Gastrointestinal stromal Tumour) and by Regional Analysis Global Forecast by 2022-2027 4-5 minutes
Sunitinib Malate is the small molecule, orally bioavailable malate salt of an indolinone-based multi-focused on receptor tyrosine kinase (RTK) inhibitor that was affirmed by the Food and Drug Administration (FDA) for the treatment of Carcinoma. The conceivable antineoplastic movement of Sunitinib has figured out how to it being seen as a viable specialist in hindering cell multiplication and angiogenesis. Sunitinib cases have been endorsed for use in treatment of Pancreatic Neuroendocrine Tumors, Kidney Cancer and Gastrointestinal Stromal Tumour (GIST). How Big is The Sunitinib Malate Market? The Sunitinib Malate Market is expected to be around US$ 190.9 Million by 2027 at a CAGR of 14% in the given forecast
03/08/2022, 22:37